Pentixapharm Restructures to Focus on Advanced Clinical Programs, Extends Financial Runway

The Managing Board and Supervisory Board of Pentixapharm Holding AG have jointly resolved to significantly reduce early-stage research and development activities while concentrating resources on the company's most advanced clinical programs. This strategic prioritization represents a continuation of the clinical development strategy introduced in May 2025 and marks a targeted approach to resource allocation within the advanced clinical-stage biotech company.

This restructuring allows Pentixapharm to invest more effectively in its most value-generating development programs, with particular focus on the Phase 3-ready CXCR4 flagship program for improved diagnosis of treatment-resistant hypertension. The CXCR4-targeted programs remain central to the company's clinical development strategy, showcasing Pentixapharm's expertise in radiopharmaceutical development. The company's clinical pipeline is anchored by CXCR4-targeted PET-CT programs, including the advanced candidate for improved diagnosis of hypertensive patients with primary aldosteronism, which aims to enable targeted treatment of underlying hypertension causes.

The organizational adjustments include a targeted workforce reduction of approximately 50% at Pentixapharm AG, with implementation anticipated to be completed in the first quarter of 2026. These measures are expected to significantly lower annual operating costs and extend the company's cash runway through the first quarter of 2027. The extended financial runway provides the company with additional stability to pursue its clinical milestones without immediate funding concerns.

Dr. Dirk Pleimes, CEO and CMO of Pentixapharm AG, emphasized the strategic importance of these measures, stating that optimizing operational costs represents a crucial step to enhance company efficiency and establish a solid foundation for achieving upcoming clinical milestones. While acknowledging the careful consideration behind the organizational restructuring, Dr. Pleimes noted that these decisions are essential to safeguard the company's long-term value and support sustainable growth.

Beyond the CXCR4 programs, Pentixapharm's development portfolio includes pioneering therapeutic programs in hematological cancers and a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. The company's position in the radiopharmaceutical sector is strengthened by comprehensive CXCR4 and CD24 intellectual property protection and a reliable isotope supply chain, positioning Pentixapharm to deliver meaningful patient benefits in one of precision medicine's fastest-growing areas. The strategic focus on advanced programs while maintaining key platform technologies demonstrates the company's balanced approach to near-term clinical advancement and long-term innovation potential in the competitive biotech landscape.